Literature DB >> 2475182

Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.

A Lichtenstein1, J Berenson, D Norman, M P Chang, A Carlile.   

Abstract

Previous work with continuously cultured multiple myeloma lines suggested that cytokine production by tumor cells may mediate some of the medical complications of this disease. To further investigate this issue, we assayed freshly obtained bone marrow (BM) cells from myeloma patients for the in vitro production of cytokines and the presence of cytokine RNA. Production of cytokine protein was assessed by bioassays with the aid of specific neutralizing anticytokine antibodies. These assays detected interleukin-1 (IL-1) and tumor necrosis factor (TNF) secretion by myeloma BM cells, which was significantly greater than secretion from similarly processed BM cells of control individuals. In contrast, lymphotoxin and interleukin-2 (IL-2) production could not be detected. The levels of IL-1 and TNF produced in vitro peaked at 24 hours of culture and correlated with stage and the presence (or absence) of extensive osteolytic bone disease. Northern blot analysis demonstrated the presence of IL-1 beta and TNF RNA in uncultured myeloma BM cells but no detectable IL-1 alpha or lymphotoxin RNA. In addition, the amount of cytokine RNA correlated with protein production, being significantly greater in patients' BM cells than in control marrow. These data suggest a role for IL-1 beta and/or TNF in the pathophysiology of multiple myeloma and argue against a role for lymphotoxin or IL-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

2.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

3.  NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells.

Authors:  Sara Zahedi; Karim Shamsasenjan; Aliakbar Movassaghpour; Parvin Akbarzadehlaleh
Journal:  Adv Pharm Bull       Date:  2016-09-25

4.  Granulocyte-colony stimulating factor concentrations in a patient with plasma cell dyscrasia and clinical features of chronic neutrophilic leukaemia.

Authors:  M Nagai; S Oda; M Iwamoto; K Marumoto; M Fujita; J Takahara
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

5.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sun; S F Lin; L Gradoville; Y Yuan; F Zhu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 6.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

Review 7.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

8.  Severe hypercalcaemia and extensive osteolytic lesions in an adult patient with T cell acute lymphoblastic leukaemia.

Authors:  P Antunovic; D Marisavljevic; N Kraguljac; V Jelusic
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

9.  INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Authors:  Jun Li; Margaret Favata; Jennifer A Kelley; Eian Caulder; Beth Thomas; Xiaoming Wen; Richard B Sparks; Ari Arvanitis; James D Rogers; Andrew P Combs; Kris Vaddi; Kimberly A Solomon; Peggy A Scherle; Robert Newton; Jordan S Fridman
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

10.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.